Literature DB >> 18544032

Genetic predisposition to breast cancer: past, present, and future.

Clare Turnbull1, Nazneen Rahman.   

Abstract

In recent years, our understanding of genetic predisposition to breast cancer has advanced significantly. Three classes of predisposition factors, categorized by their associated risks of breast cancer, are currently known. BRCA1 and BRCA2 are high-penetrance breast cancer predisposition genes identified by genome-wide linkage analysis and positional cloning. Mutational screening of genes functionally related to BRCA1 and/or BRCA2 has revealed four genes, CHEK2, ATM, BRIP1, and PALB2; mutations in these genes are rare and confer an intermediate risk of breast cancer. Association studies have further identified eight common variants associated with low-penetrance breast cancer predisposition. Despite these discoveries, most of the familial risk of breast cancer remains unexplained. In this review, we describe the known genetic predisposition factors, expound on the methods by which they were identified, and consider how further technological and intellectual advances may assist in identifying the remaining genetic factors underlying breast cancer susceptibility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544032     DOI: 10.1146/annurev.genom.9.081307.164339

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  111 in total

Review 1.  Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.

Authors:  Alfons Meindl; Nina Ditsch; Karin Kast; Kerstin Rhiem; Rita K Schmutzler
Journal:  Dtsch Arztebl Int       Date:  2011-05-13       Impact factor: 5.594

2.  Novel germline PALB2 truncating mutations in African American breast cancer patients.

Authors:  Yonglan Zheng; Jing Zhang; Qun Niu; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

3.  Functional variable number of tandem repeats variation in the promoter of proto-oncogene PTTG1IP is associated with risk of estrogen receptor-positive breast cancer.

Authors:  Chan Xiang; Haidong Gao; Lei Meng; Zhaoyu Qin; Rong Ma; Yang Liu; Yan Jiang; Chengxue Dang; Li Jin; Fuchu He; Haijian Wang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

4.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

Review 5.  Repair of strand breaks by homologous recombination.

Authors:  Maria Jasin; Rodney Rothstein
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

6.  Rare Coding Variants Associated with Breast Cancer.

Authors:  Mi-Ryung Han
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Identification of Novel Susceptibility Genes for Breast Cancer - Genome-Wide Association Studies or Evaluation of Candidate Genes?

Authors:  Alfons Meindl
Journal:  Breast Care (Basel)       Date:  2009-04-24       Impact factor: 2.860

8.  TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.

Authors:  J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

Review 9.  Polygenic susceptibility to breast cancer: current state-of-the-art.

Authors:  Maya Ghoussaini; Paul D P Pharoah
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

10.  Knowledge and perceptions of familial and genetic risks for breast cancer risk in adolescent girls.

Authors:  Angela R Bradbury; Linda Patrick-Miller; Brian L Egleston; Lisa A Schwartz; Colleen B Sands; Rebecca Shorter; Cynthia W Moore; Lisa Tuchman; Paula Rauch; Shreya Malhotra; Brianne Rowan; Stephanie Van Decker; Helen Schmidheiser; Lisa Bealin; Patrick Sicilia; Mary B Daly
Journal:  Breast Cancer Res Treat       Date:  2012-10-14       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.